Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Measurement of charged particle spectra in minimum-bias events from proton-proton collisions at <math> </math>.

The European physical journal. C, Particles and fields·2019
Same author

Search for single production of vector-like quarks decaying to a top quark and a <math></math> boson in proton-proton collisions at <math> </math>.

The European physical journal. C, Particles and fields·2019
Same author

Calcification of Dental Pulps.

The American journal of dental science·2019
Same author

Search for the Higgs Boson Decaying to Two Muons in Proton-Proton Collisions at sqrt[s]=13  TeV.

Physical review letters·2019
Same author

Search for Leptoquarks Coupled to Third-Generation Quarks in Proton-Proton Collisions at sqrt[s]=13  TeV.

Physical review letters·2019
Same author

Observation of Medium-Induced Modifications of Jet Fragmentation in Pb-Pb Collisions at sqrt[s_{NN}]=5.02  TeV Using Isolated Photon-Tagged Jets.

Physical review letters·2019

Related Experiment Video

Updated: Jul 4, 2026

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
11:02

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Published on: October 30, 2013

[Targeted therapy for metastatic bladder cancer].

F Vom Dorp1, C Börgermann, A Rose

  • 1Klinik und Poliklinik für Urologie, Universitätsklinikum, Hufelandstrasse 55, 45122 Essen, Deutschland. frankvomDorp@web.de

Der Urologe. Ausg. A
|July 1, 2008
PubMed
Summary

Metastatic bladder cancer treatment remains challenging, with limited progress in chemotherapy. Targeted therapy using growth factor receptor inhibitors shows promise for improving outcomes in advanced bladder cancer.

More Related Videos

An Orthotopic Bladder Cancer Model for Gene Delivery Studies
07:48

An Orthotopic Bladder Cancer Model for Gene Delivery Studies

Published on: December 1, 2013

Related Experiment Videos

Last Updated: Jul 4, 2026

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
11:02

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Published on: October 30, 2013

An Orthotopic Bladder Cancer Model for Gene Delivery Studies
07:48

An Orthotopic Bladder Cancer Model for Gene Delivery Studies

Published on: December 1, 2013

Area of Science:

  • Oncology
  • Pharmacology
  • Cancer Biology

Background:

  • Current first-line chemotherapy for metastatic bladder cancer (gemcitabine and cisplatin) has shown limited efficacy over the past 20 years, with a median survival of only 14 months.
  • Despite extensive research into various protocols, significant advancements in treating metastatic bladder cancer have been minimal.
  • Expression analysis of growth factor receptors in tumor tissues indicates a correlation between specific receptor expression and a more severe clinical progression.

Purpose of the Study:

  • To review current studies on targeted therapy for metastatic bladder carcinoma.
  • To explore the potential of pharmacological inhibitors targeting growth factor receptors for advanced bladder cancer treatment.

Main Methods:

  • Literature review of current studies on targeted therapy for metastatic bladder carcinoma.
  • Analysis of expression patterns of growth factor receptors in human bladder tumor tissue.
  • Identification of pharmacological inhibitors for relevant growth factor receptors.

Main Results:

  • Expression of certain growth factor receptors is associated with a poorer prognosis in metastatic bladder cancer.
  • Pharmacological inhibitors targeting these growth factor receptors are available for therapeutic intervention.
  • Targeted therapy represents a promising avenue for improving treatment outcomes.

Conclusions:

  • Targeted therapies offer a potential new strategy for managing metastatic bladder cancer, moving beyond traditional chemotherapy limitations.
  • Further research and clinical trials are warranted to establish the efficacy and safety of targeted therapies in this patient population.
  • Personalized treatment approaches based on growth factor receptor expression may enhance therapeutic effectiveness.